Displaying 37 - 48 of 122
Viral Hepatitis
5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View
Viral Hepatitis
5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View
Viral Hepatitis
5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View
Metabolism, Alcohol & Toxicity
5

Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022

View
Metabolism, Alcohol & Toxicity
5

Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022

View
Metabolism, Alcohol & Toxicity
5

Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022

View
Metabolism, Alcohol & Toxicity
5

Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022

View
Metabolism, Alcohol & Toxicity
6

Perspectum: Advances in non-invasive imaging for NAFLD / NASH - ILC 2022

View
Viral Hepatitis
6

AbbVie: An HCV-Free Future - It Always Seems Impossible Until It's Done - ILC 2022

View
Viral Hepatitis
6

AbbVie: An HCV-Free Future - It Always Seems Impossible Until It's Done - ILC 2022

View
Viral Hepatitis
6

AbbVie: An HCV-Free Future - It Always Seems Impossible Until It's Done - ILC 2022

View
Viral Hepatitis
6

AbbVie: An HCV-Free Future - It Always Seems Impossible Until It's Done - ILC 2022

View
Displaying 37 - 48 of 122